You are here: Industry Insights > chronic pain

News List

Navega Therapeutics expands its Scientific Advisory Board with the addition of pain expert Stephen Waxman. firstwordpharma
August 25, 2021
Navega Therapeutics, a San Diego-based biotechnology company developing epigenetic gene therapies, has announced that it is expanding its Scientific Advisory Board ("SAB") to include Dr. Stephen Waxman, MD, PhD.
Interaxon Partners with Celéri Health to Validate Chronic Pain Intervention prnasia
July 21, 2021
Interaxon, along with Celéri Health and pain expert Dr. Ronald D. Siegel, is testing a therapeutic intervention to help people better manage their chronic and acute pain.
Lilly Acquires Asahi Kasei’s Chronic Pain Candidate contractpharma
February 02, 2021
Eli Lilly and Co. and Asahi Kasei Pharma entered a license agreement under which Lilly will acquire the exclusive rights for AK1780 from Asahi Kasei Pharma.
NICE updates guidance on chronic pain treatments pharmatimes
August 07, 2020
The UK’s National Institute for Health and Care Excellence (NICE) has published draft guidance which details how some commonly used drug treatments for chronic primary pain have little to no effect.
Commonly used treatments for chronic pain do not work, says NICE europeanpharmaceuticalreview
August 06, 2020
NICE has said commonly used treatments for chronic primary pain such as paracetamol have little or no evidence that they work and should not be prescribed for the condition.
Imbrium Therapeutics and TetraGenetics Announce Strategic Research Collaboration and License Option to Develop Novel Biologic Therapeutics pharmafocusasia
February 28, 2019
Imbrium Therapeutics L.P., a clinical-stage biopharmaceutical company and operating subsidiary of Purdue Pharma L.P., and TetraGenetics, Inc....
Purdue Pharma taps TetraGenetics for ion channel-focused pain treatments in $273M discovery pact fiercebiotech
February 27, 2019
Purdue Pharma’s newly formed clinical research subsidiary, Imbrium Therapeutics, has tapped TetraGenetics and its antibody discovery platform to help it develop new, non-opioid-based biologics for treating chronic pain....
CDC: About One in Five U.S. Adults Have Chronic Pain drugs
September 14, 2018
About 20.4 percent of U.S. adults have chronic pain and 8.0 percent have high-impact chronic pain, according to research published in the Sept. 14 issue of the U.S. Centers for Disease Control and Prevention's Morbidity and Mortality Weekly Report.
Teikoku Pharma Announces Positive Results from Phase 2 Clinical Trial of TPU-006 americanpharmaceuticalreview
August 24, 2017
Teikoku Pharma announced positive topline results from its Phase 2 proof of concept study of TPU-006, a three-day dexmedetomidine transdermal patch, a novel drug delivery system with a non-opioid active moiety for the management of post-surgical pain.